Safety and Efficacy of Intravitreal Ranibizumab for Diabetic Macular Edema Previously Treated With Intravitreal Bevacizumab: A Randomized Dual Arm Comparative Dosing Trial
Latest Information Update: 03 Aug 2017
Price :
$35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms REACT
- 05 Jul 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2018.
- 01 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.